S'abonner

Screening and vaccination against COVID-19 to minimise school closure: a modelling study - 23/06/22

Doi : 10.1016/S1473-3099(22)00138-4 
Elisabetta Colosi, MSc a, Giulia Bassignana, PhD a, Diego Andrés Contreras, PhD b, Canelle Poirier, PhD a, Pierre-Yves Boëlle, ProfPhD a, Simon Cauchemez, PhD c, Yazdan Yazdanpanah, ProfPhD d, e, Bruno Lina, ProfPhD f, g, Arnaud Fontanet, ProfPhD h, i, Alain Barrat, PhD b, j, Vittoria Colizza, PhD a, j,
a INSERM, Sorbonne Université, Pierre Louis Institute of Epidemiology and Public Health, Paris, France 
b Aix-Marseille Univ, Université de Toulon, CNRS, Centre de Physique Théorique, Turing Center for Living Systems, Marseille, France 
c Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France 
d Infection, Antimicrobials, Modelling, Evolution, INSERM, Université de Paris, Paris, France 
e Bichat Claude Bernard Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France 
f National Reference Center for Respiratory Viruses, Department of Virology, Infective Agents Institute, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France 
g Virpath Laboratory, International Center of Research in Infectiology, INSERM U1111, CNRS–UMR 5308, École Normale Supérieure de Lyon, Université Claude Bernard Lyon, Lyon University, Lyon, France 
h Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France 
i PACRI Unit, Conservatoire National des Arts et Metiers, Paris, France 
j Tokyo Tech World Research Hub Initiative, Tokyo Institute of Technology, Tokyo, Japan 

* Correspondence to: Dr Vittoria Colizza, INSERM, Sorbonne Université, Pierre Louis Institute of Epidemiology and Public Health, Paris 75012, France INSERM, Sorbonne Université Pierre Louis Institute of Epidemiology and Public Health Paris 75012 France

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Summary

Background

Schools were closed extensively in 2020–21 to counter SARS-CoV-2 spread, impacting students’ education and wellbeing. With highly contagious variants expanding in Europe, safe options to maintain schools open are urgently needed. By estimating school-specific transmissibility, our study evaluates costs and benefits of different protocols for SARS-CoV-2 control at school.

Methods

We developed an agent-based model of SARS-CoV-2 transmission in schools. We used empirical contact data in a primary and a secondary school and data from pilot screenings in 683 schools during the alpha variant (B.1.1.7) wave in March–June, 2021, in France. We fitted the model to observed school prevalence to estimate the school-specific effective reproductive number for the alpha (Ralpha) and delta (B.1.617.2; Rdelta) variants and performed a cost–benefit analysis examining different intervention protocols.

Findings

We estimated Ralpha to be 1·40 (95% CI 1·35–1·45) in the primary school and 1·46 (1·41–1·51) in the secondary school during the spring wave, higher than the time-varying reproductive number estimated from community surveillance. Considering the delta variant and vaccination coverage in Europe as of mid-September, 2021, we estimated Rdelta to be 1·66 (1·60–1·71) in primary schools and 1·10 (1·06–1·14) in secondary schools. Under these conditions, weekly testing of 75% of unvaccinated students (PCR tests on saliva samples in primary schools and lateral flow tests in secondary schools), in addition to symptom-based testing, would reduce cases by 34% (95% CI 32–36) in primary schools and 36% (35–39) in secondary schools compared with symptom-based testing alone. Insufficient adherence was recorded in pilot screening (median ≤53%). Regular testing would also reduce student-days lost up to 80% compared with reactive class closures. Moderate vaccination coverage in students would still benefit from regular testing for additional control—ie, weekly testing 75% of unvaccinated students would reduce cases compared with symptom-based testing only, by 23% in primary schools when 50% of children are vaccinated.

Interpretation

The COVID-19 pandemic will probably continue to pose a risk to the safe and normal functioning of schools. Extending vaccination coverage in students, complemented by regular testing with good adherence, are essential steps to keep schools open when highly transmissible variants are circulating.

Funding

EU Framework Programme for Research and Innovation Horizon 2020, Horizon Europe Framework Programme, Agence Nationale de la Recherche, ANRS–Maladies Infectieuses Émergentes.

Le texte complet de cet article est disponible en PDF.

Plan


© 2022  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 22 - N° 7

P. 977-989 - juillet 2022 Retour au numéro
Article précédent Article précédent
  • Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study
  • Peter Bager, Jan Wohlfahrt, Samir Bhatt, Marc Stegger, Rebecca Legarth, Camilla Holten Møller, Robert Leo Skov, Palle Valentiner-Branth, Marianne Voldstedlund, Thea K Fischer, Lone Simonsen, Nikolai Søren Kirkby, Marianne Kragh Thomsen, Katja Spiess, Ellinor Marving, Nicolai Balle Larsen, Troels Lillebaek, Henrik Ullum, Kåre Mølbak, Tyra Grove Krause, the Omicron-Delta study group, Sofie Marie Edslev, Raphael Niklaus Sieber, Anna Cäcilia Ingham, Maria Overvad, Mie Agermose Gram, Frederikke Kristensen Lomholt, Louise Hallundbæk, Caroline Hjorth Espensen, Sophie Gubbels, Marianne Karakis, Karina Lauenborg Møller, Stefan Schytte Olsen, Zitta Barrella Harboe, Caroline Klint Johannesen, Maarten van Wijhe, Jon Gitz Holler, Ram Benny Christian Dessau, Martin Barfred Friis, David Fuglsang-Damgaard, Mette Pinholt, Thomas Vognbjerg Sydenham, John Eugenio Coia, Ea Sofie Marmolin, Anders Fomsgaard, Jannik Fonager, Morten Rasmussen, Arieh Cohen
| Article suivant Article suivant
  • Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial
  • Igor Smolenov, Htay Htay Han, Ping Li, Carmen Baccarini, Carole Verhoeven, Frank Rockhold, Sue Ann Costa Clemens, Donna Ambrosino, Peter Richmond, George Siber, Joshua Liang, Ralf Clemens, SPECTRA Study Group

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.